US

Who we are

Chiesi has been focused on the centrality of the patient for decades. In 2019, Chiesi created a unit specifically dedicated to the development and commercialization of products for rare diseases to further increase our focus on the patients.

Patients have been at the center of what we do for decades.

We believe that no patient should be left behind, which is why we created a business unit specifically dedicated to those with rare diseases. Patients with rare diseases can encounter many difficulties, from getting a timely and accurate diagnosis, to accessing effective medical and social care, resulting in heavy burdens on patients.1 As such, we believe this therapeutic area to be of great importance and impact.

In 2019, the Chiesi Group launched Rare Diseases, a business unit that works in collaboration with other functions of the Chiesi Group while maintaining an exclusive focus to develop and commercialize products that help to address the unique needs of patients with rare diseases.

YEARS OF RESEARCH & INNOVATION IN OUR DNA.
CHIESI IN THE WORLD2
Founded over 85 years ago, Chiesi is a family-controlled, Italian pharmaceutical company. Chiesi Group is a certified B Corp and employs around 5,700 people with a Global presence.

 

Chiesi in the World
  1. Gainotti S, et al. Int J Environ Res Public Health 2018; 15(10): 2072.
  2. Chiesi 2018 Annual Report. Available at: https://www.chiesi.com/flipbook.php?url=https://www.chiesi.com/img/annual_report/documenti/29_annual-report-2018-_-english.pdf. Last accessed: December 19, 2019.